OncoNano awarded £12.6m grant from Cancer Prevention and Research Institute of Texas

This article was originally published here

In ONM-500, OncoNano leverages its proprietary pH-sensitive micelle technology to deliver antigens while activating innate immunity for the treatment of cancers caused by the human papilloma virus (HPV).

The post OncoNano awarded £12.6m grant from Cancer Prevention and Research Institute of Texas appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply